UPDATE: AstraZeneca (AZN), Sanofi (SNY) Settle Diabetes Drug Patent Suit
Get Alerts AZN Hot Sheet
Join SI Premium – FREE
(Updated - October 4, 2016 12:05 PM EDT)
AstraZeneca (NYSE: AZN) and Sanofi (NYSE: SNY) have settled a patent dispute over diabetes drugs, according to Bloomberg.
One spokesperson for Sanofi said, Sanofi is pleased that the pathway, upon appropriate regulatory approval, is clear to bring Adlyxin (Lixisenatide) and investigational iGlarLixi as new treatment options for adults living with type 2 diabetes in the U.S.
Adlyxin received FDA approval in July, while the agency delayed approval of iGlarLixi until November.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)
- The Carlyle Group (CG) Announces COO Change
- AstraZeneca's (AZN) Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer
Create E-mail Alert Related Categories
Corporate News, Insiders' Blog, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!